# Cohance Lifesciences (COHANCE) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/cohance

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹433
- Change: -3.56%
- As of: 2026-11-06
- 1D return: -3.56%
- 5D return: -2.54%
- 1M return: -2.12%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

COHANCE closed at ₹433.0 on 2026-11-06, following a high-severity downward gap of -3.6% and an extreme intraday range event on 2026-10-30 (-7.7%). The stock is in a significant downtrend, trading 60.9% below its available high and sitting near the lower end of its 20-day (+11.8%) and 50-day (+21.9%) ranges. While the daily Supertrend remains bullish with price above the 200-period SMA, momentum indicators are weak (ADX 14.19) and price has broken below key short-term averages (20/50 EMA/SMA). A Bearish Engulfing Reversal pattern formed on the monthly timeframe today, reinforcing the bearish bias despite conflicting weekly signals. Risk remains elevated with annualized volatility of +46.6% and a current drawdown of -60.9%.

- Price Action: Closed at ₹433.0 after a -3.6% downward gap; nearest resistance at ₹433.32 (0.07% above) and support at ₹429.77 (0.74% below).
- Trend Structure: Monthly trend is strongly bearish (Supertrend bearish, ADX 42.52); Daily trend shows weak momentum (ADX 14.19) with price below 20/50 EMAs but above 200 SMA.
- Risk Metrics: Current drawdown stands at -60.9% from available highs; annualized volatility is +46.6% with an ATR of 4.1%, indicating high price sensitivity.
- Confirmation/Invalidation: A close above ₹439.96 (1.61% resistance) would be required to challenge the immediate bearish structure; failure to hold above ₹429.77 increases downside risk toward ₹416.80 (-3.74%).

- Bearish Engulfing Reversal
- Bullish Engulfing Reversal
- Doji
- Harami

### News Context

On November 6, 2026, Cohance Lifesciences faced a regulatory shutdown of its manufacturing facility in Suryapet, Telangana, after the state pollution control board ordered closure following a fatal industrial accident. The company confirmed it is implementing corrective and preventive measures to address regulatory observations and intends to submit compliance documents promptly to resume operations. While the specific operational impact on production capacity remains undefined, the immediate cessation of activities at this site represents a direct disruption to business continuity. In market commentary from the same date, analysts maintained a 12-month target price of ₹472 for the stock, though this valuation view exists alongside active operational and regulatory risks.

- Regulatory Action: The Telangana Pollution Control Board ordered the closure of the Suryapet manufacturing site on November 6, 2026, following a worker fatality.
- Company Response: Cohance Lifesciences stated it is implementing corrective measures and plans to submit compliance documents to seek resumption of operations.
- Market View: Analysts cited in reports on November 6, 2026, maintain a 12-month target price of ₹472 for the equity.

- [Cohance Lifesciences manufacturing site in Telangana shut after worker dies in accident](https://www.thehindubusinessline.com/companies/cohance-lifesciences-manufacturing-site-in-telanganashut-after-worker-dies-in-accident/article71672770.ece)
- [Cohance Lifesciences plant ordered shut in Telangana after employee dies in industrial accident](https://www.moneycontrol.com/news/business/cohance-lifesciences-plant-ordered-shut-in-telangana-after-employee-dies-in-industrial-accident-14072157.html)
- [Cohance shares in focus as Telangana site closed after industrial accident](https://www.businesstoday.in/markets/stocks/story/cohance-shares-in-focus-as-telangana-site-closed-after-industrial-accident-566084-2026-11-06)

### What Changed

On 6 November 2026, Cohance Lifesciences faces a dual development involving regulatory action and corporate capital activity. The Telangana Pollution Control Board ordered the immediate shutdown of the company’s Suryapet manufacturing site following a fatal industrial accident. While the company has initiated corrective measures and plans to submit compliance documents to resume operations, this closure introduces operational uncertainty for the facility.

Simultaneously, the Nomination and Remuneration Committee approved the grant of 172,570 stock options across ESOP 2026 and ESOP 2023 plans, alongside the allotment of 25,600 equity shares upon the exercise of vested options. These new shares, issued at an exercise price of ₹268 per share with a face value of ₹1, increased the total issued share capital to ₹38,26,22,930. Market data recorded on the same date shows the share price at ₹433.00, down from a previous reference level of ₹450.45.

- Regulatory Shutdown: The Telangana Pollution Control Board ordered the closure of the Suryapet manufacturing site after a fatal industrial accident; the company is implementing corrective measures to seek resumption of operations.
- ESOP Activity: On 6 November 2026, the company granted 172,570 stock options and allotted 25,600 equity shares (issued at ₹268/share), raising total issued share capital to ₹38,26,22,930.
- Price Movement: The stock traded at ₹433.00 on 6 November 2026, reflecting a decline from the previous reported level of ₹450.45.

- [Cohance Lifesciences manufacturing site in Telangana shut after worker dies in accident](https://www.thehindubusinessline.com/companies/cohance-lifesciences-manufacturing-site-in-telanganashut-after-worker-dies-in-accident/article71672770.ece)
- [Cohance Lifesciences plant ordered shut in Telangana after employee dies in industrial accident](https://www.moneycontrol.com/news/business/cohance-lifesciences-plant-ordered-shut-in-telangana-after-employee-dies-in-industrial-accident-14072157.html)
- [Cohance shares in focus as Telangana site closed after industrial accident](https://www.businesstoday.in/markets/stocks/story/cohance-shares-in-focus-as-telangana-site-closed-after-industrial-accident-566084-2026-11-06)
- [Cohance Lifesciences Limited has informed the Exchange about Grant of Stock Options to Certain Eligible Employees of the Company and Allotment of Equity Shares Pursuant to Exercise of Stock Options |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_06112026131252_Cohance_SE_disclosure_ESOP_06112026.pdf)

### Official Filings

Cohance Lifesciences faces immediate operational disruption after the Telangana Pollution Control Board issued a closure order on November 5, 2026, suspending manufacturing at its Suryapet facility following an industrial accident. The company intends to seek cancellation of the order but cannot quantify financial impacts at this stage. Concurrently, the Board approved unaudited Q2 and H1 FY27 results on November 6, with investor discussions scheduled for that day. Leadership changes include Umang Vohra’s appointment as Chairman and Group CEO (approved October 8) and Abhimanyu Ojha joining as CFO effective October 12. On the capital front, the company allotted 25,600 equity shares at ₹268 per share via ESOP exercises, raising total share capital to ₹38,26,22,930.

- Regulatory Action: Manufacturing suspended at Suryapet facility by Telangana Pollution Control Board on November 5, 2026; operational impact unquantified.
- Financial Reporting: Board approved Q2 and H1 FY27 unaudited results on November 6, 2026.
- Leadership Updates: Umang Vohra appointed Chairman/Group CEO (MCA approved Oct 8); Abhimanyu Ojha appointed CFO effective Oct 12.
- Capital Structure: 25,600 shares allotted at ₹268 each via ESOP exercise; total share capital increased to ₹38,26,22,930.

- [Cohance Lifesciences Limited has informed the Exchange about General Updates |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_06112026082040_Cohance_PCB_order_disclosure_6Nov26.pdf)
- [Cohance Lifesciences Limited has informed the Exchange about Grant of Stock Options to Certain Eligible Employees of the Company and Allotment of Equity Shares Pursuant to Exercise of Stock Options |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_06112026131252_Cohance_SE_disclosure_ESOP_06112026.pdf)
- [Cohance Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_03112026193202_Cohance_Q2_Concal_Invite_06112026_.pdf)
- [Cohance Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_27102026125928_Cohance_Q2_Concal_Invite_06112026_.pdf)
- [Financial Results |Meeting Date: 06-Nov-2026](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_26102026181153_Cohance_BM_Intimation_06112026.pdf)
- [Board Meeting Intimation |Meeting Date: 06-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_17775_WebXMLFile_20261026_181859117.xml)
- [Cohance Lifesciences Limited has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_17775_WebXMLFile_20261026_181859117.xml)
- [AS ON DATE : 30-Sep-2026 | PR_AND_PRGRP: 57.48 | PUBLIC_VAL: 42.52 | EMPTR: 0 | NDS_REVISED_STATUS: - | SUBMISSION_DT: 15-Oct-2026 | REVISION_DT: -](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1739335_15102026071315_WEB.xml)
- [Cohance Lifesciences Limited has informed the Exchange about General Updates |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_12102026194926_SE_disclosure_CG_Approval_Umang_Vohra.pdf)
- [Cohance Lifesciences Limited has informed the Exchange regarding Appointment of Mr Abhimanyu Ojha as Chief Financial Officer of the company w.e.f. October 12, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_09102026201959_Cohance_Outcome_BM_09102026.pdf)

### Fundamentals

Cohance Lifesciences is navigating a sharp deterioration in profitability and cash generation. In Q1 FY2026-27, the company reported a net loss of ₹45.19 crore, reversing the ₹8.31 crore profit in Q4 FY2025-26, driven by a sequential revenue drop to ₹422.26 crore from ₹619.12 crore. This aligns with a trailing twelve-month (TTM) sales decline of 20% and a TTM net profit plunge of 77%. While finance costs decreased sequentially to ₹6.74 crore, operating leverage remains under pressure as depreciation rose to ₹44.0 crore in Sep 2025. Balance-sheet expansion has been aggressive; borrowings surged from ₹65.0 crore in Mar 2024 to ₹486.0 crore in Mar 2025 before easing slightly to ₹400.0 crore in Mar 2026, while fixed assets grew nearly five-fold over three years. Despite this capital intensity, return metrics have weakened significantly, with ROCE falling from 21.0% in Mar 2025 to 6.0% in Mar 2026. Cash conversion efficiency also declined, with CFO/EBITDA dropping from 107.0 to 102.0, and working capital days increasing to 133.0 in Mar 2026.

- Q1 FY2026-27 Net Profit: -₹45.19 crore (loss), compared to ₹8.31 crore profit in Q4 FY2025-26.
- TTM Sales Growth: -20%; TTM Compounded Profit Growth: -77%.
- ROCE Decline: Fell from 21.0% (Mar 2025) to 6.0% (Mar 2026).
- Borrowings: ₹400.0 crore (Mar 2026), down from peak of ₹486.0 crore (Mar 2025).
- Next Checkpoint: Monitor if Q2 FY2026-27 revenue stabilizes above ₹422.26 crore and if operating margins recover from negative pre-tax territory.

### Bear Case

Cohance Lifesciences faces immediate operational and regulatory headwinds after the Telangana Pollution Control Board ordered the closure of its Suryapet manufacturing site following a fatal industrial accident. The company has initiated corrective measures and plans to submit compliance documents, but the shutdown introduces uncertainty regarding production continuity and potential penalties. From a market perspective, the stock is in a pronounced downtrend, having fallen 40.2% over the past year and 17.3% year-to-date as of November 6, 2026. Technical indicators on the monthly timeframe are bearish, with the SuperTrend direction signaling downside pressure. The stock currently trades at ₹433.00, near a critical support level at ₹429.77, while resistance remains close at ₹433.32. With an annualized volatility of 46.6% and a current drawdown of -60.9%, the equity exhibits high risk and significant recent underperformance relative to broader trends.

- Regulatory Shutdown: The Telangana Pollution Control Board ordered the closure of the Suryapet manufacturing site following a fatal accident; operations remain halted pending submission of compliance documents.
- Poor Price Performance: Shares have declined 40.2% over the last 12 months and 17.3% year-to-date, closing at ₹433.00 on November 6, 2026.
- Bearish Technical Setup: Monthly trend indicators show a bearish SuperTrend direction, with the stock trading near support at ₹429.77 and facing immediate resistance at ₹433.32.
- Elevated Volatility and Drawdown: The stock carries an annualized volatility of 46.6% and a current drawdown of -60.9%, reflecting substantial recent price erosion and risk.

- [Cohance Lifesciences manufacturing site in Telangana shut after worker dies in accident](https://www.thehindubusinessline.com/companies/cohance-lifesciences-manufacturing-site-in-telanganashut-after-worker-dies-in-accident/article71672770.ece)
- [Cohance Lifesciences plant ordered shut in Telangana after employee dies in industrial accident](https://www.moneycontrol.com/news/business/cohance-lifesciences-plant-ordered-shut-in-telangana-after-employee-dies-in-industrial-accident-14072157.html)
- [Cohance shares in focus as Telangana site closed after industrial accident](https://www.businesstoday.in/markets/stocks/story/cohance-shares-in-focus-as-telangana-site-closed-after-industrial-accident-566084-2026-11-06)
- [Cohance Lifesciences Limited has informed the Exchange about General Updates |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_06112026082040_Cohance_PCB_order_disclosure_6Nov26.pdf)
- [Cohance Lifesciences Limited has informed the Exchange about Grant of Stock Options to Certain Eligible Employees of the Company and Allotment of Equity Shares Pursuant to Exercise of Stock Options |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_06112026131252_Cohance_SE_disclosure_ESOP_06112026.pdf)
- [Cohance Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_03112026193202_Cohance_Q2_Concal_Invite_06112026_.pdf)
- [Cohance Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_27102026125928_Cohance_Q2_Concal_Invite_06112026_.pdf)
- [Financial Results |Meeting Date: 06-Nov-2026](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_26102026181153_Cohance_BM_Intimation_06112026.pdf)
- [Board Meeting Intimation |Meeting Date: 06-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_17775_WebXMLFile_20261026_181859117.xml)
- [Cohance Lifesciences Limited has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_17775_WebXMLFile_20261026_181859117.xml)

### FAQs

**What regulatory action has been taken against Cohance Lifesciences' manufacturing operations?**

On November 5, 2026, the Telangana Pollution Control Board ordered the immediate suspension of manufacturing activities at the company’s Suryapet facility following a fatal industrial accident. The order cites alleged non-compliances with safety measures under applicable consent conditions. The company has initiated corrective and preventive measures and intends to submit representations to seek cancellation of the closure.

**How is the company quantifying the financial impact of the plant shutdown?**

Cohance Lifesciences disclosed in an NSE filing on November 6, 2026, that the operational and financial impact of the closure cannot be quantified with reasonable certainty at this stage. This uncertainty remains pending the outcome of the company's representations to regulators and the timeline for resuming operations.

**What corporate actions have occurred regarding share capital recently?**

On November 6, 2026, the Nomination and Remuneration Committee approved the grant of 172,570 stock options across ESOP 2026 and ESOP 2023 plans. Additionally, 25,600 equity shares were allotted pursuant to the exercise of vested options under ESOP 2023 at an exercise price of ₹268 per share, increasing total issued share capital to ₹38,26,22,930.

**What are the key technical levels and recent performance metrics for the stock?**

As of November 6, 2026, the stock closed at ₹433.00, down from a previous close of ₹449.00. Key resistance levels are noted at ₹433.32 and ₹439.96, while support exists at ₹429.77 and ₹416.80. The stock has declined 40.2% over the past year and is currently experiencing a drawdown of -60.9%, with annualized volatility at +46.6%.

- [Cohance Lifesciences manufacturing site in Telangana shut after worker dies in accident](https://www.thehindubusinessline.com/companies/cohance-lifesciences-manufacturing-site-in-telanganashut-after-worker-dies-in-accident/article71672770.ece)
- [Cohance Lifesciences plant ordered shut in Telangana after employee dies in industrial accident](https://www.moneycontrol.com/news/business/cohance-lifesciences-plant-ordered-shut-in-telangana-after-employee-dies-in-industrial-accident-14072157.html)
- [Cohance shares in focus as Telangana site closed after industrial accident](https://www.businesstoday.in/markets/stocks/story/cohance-shares-in-focus-as-telangana-site-closed-after-industrial-accident-566084-2026-11-06)
- [Cohance Lifesciences Limited has informed the Exchange about General Updates |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_06112026082040_Cohance_PCB_order_disclosure_6Nov26.pdf)
- [Cohance Lifesciences Limited has informed the Exchange about Grant of Stock Options to Certain Eligible Employees of the Company and Allotment of Equity Shares Pursuant to Exercise of Stock Options |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_06112026131252_Cohance_SE_disclosure_ESOP_06112026.pdf)
- [Cohance Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_03112026193202_Cohance_Q2_Concal_Invite_06112026_.pdf)
- [Cohance Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_27102026125928_Cohance_Q2_Concal_Invite_06112026_.pdf)
- [Financial Results |Meeting Date: 06-Nov-2026](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_26102026181153_Cohance_BM_Intimation_06112026.pdf)
- [Board Meeting Intimation |Meeting Date: 06-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_17775_WebXMLFile_20261026_181859117.xml)
- [Cohance Lifesciences Limited has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_17775_WebXMLFile_20261026_181859117.xml)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹451.38
- Risk regime: Higher Price Risk

### Support levels
- 429.775
- 416.79999999999995
- 391.05

### Resistance levels
- 439.96015624999995
- 456.3
- 472.7875

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -3.56% |
| return_10 | -3.75% |
| return_1m | -5.25% |
| return_1y | -40.18% |
| return_20 | -2.12% |
| return_3m | -1.34% |
| return_5 | -2.54% |
| return_6m | -10.03% |
| return_since_start | -59.48% |
| return_ytd | -17.29% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -74.76% |
| annualized_volatility | +46.60% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Cohance Lifesciences Q2 FY2026-27: Revenue rebounds 12.9% sequentially

Cohance Lifesciences’ Q2 FY2026-27 revenue from operations rose 12.9% quarter on quarter to ₹476.65 crore, but remained 14.2% below the year-earlier quarter. The pre-tax loss narrowed to ₹10.75 crore from ₹42.87 crore in Q1; a ₹13.02 crore tax benefit lifted the quarter to a reported profit of ₹2.27 crore.

## Revenue recovers sequentially, remains below last year

Revenue from operations increased from ₹422.26 crore in Q1 FY2026-27 to ₹476.65 crore in Q2. Total income, including ₹12.41 crore of other income, was ₹489.06 crore, up 12.6% sequentially. Revenue remained below ₹544.55 crore in Q3 FY2025-26 and ₹619.12 crore in Q4 FY2025-26, as well as the ₹555.57 crore recorded in Q2 FY2025-26.

## Lower expense growth narrows the pre-tax loss

Expenses rose 4.7% sequentially to ₹499.81 crore, less than the 12.6% increase in total income. The pre-tax loss consequently narrowed to ₹10.75 crore from ₹42.87 crore in Q1 FY2026-27. Other expenses declined 11.5% to ₹148.64 crore from ₹167.86 crore, while finance costs increased to ₹8.37 crore from ₹6.74 crore. Depreciation and amortisation expense was ₹50.17 crore.

The improvement remains partial: Cohance recorded pre-tax profits of ₹40.60 crore in Q3 FY2025-26 and ₹19.91 crore in Q4 FY2025-26. Q2’s pre-tax result was also below the ₹83.77 crore profit in Q2 FY2025-26.

## Tax benefit lifts reported profit above break-even

A ₹13.02 crore tax benefit—comprising current and deferred tax benefits—more than offset the ₹10.75 crore pre-tax loss, resulting in reported profit of ₹2.27 crore. Profit attributable to owners of the parent was ₹15.22 crore, while non-controlling interests recorded a loss of ₹12.95 crore. Basic EPS from continuing operations was ₹0.40, compared with a loss of ₹0.63 in Q1 FY2026-27; trailing twelve-month EPS was ₹1.24.

## Cash flow and balance sheet

Cash flow from operating activities was ₹188.06 crore in the quarter. Investing and financing activities used ₹46.69 crore and ₹92.47 crore, respectively, and reported free cash flow was ₹141.37 crore. Cash and cash equivalents stood at ₹98.63 crore at 30 September 2026, up from ₹49.14 crore at 31 March 2026.

Trade receivables were ₹469.02 crore at 30 September, down from ₹681.01 crore at 31 March, while inventories increased to ₹734.34 crore from ₹562.23 crore. Goodwill was ₹1,290.19 crore and non-current investments were ₹265.91 crore at quarter-end.

## Key Takeaway

Q2 delivered a sequential revenue recovery and a narrower pre-tax loss, with a tax benefit returning reported profit to positive territory. Revenue remained below the year-earlier quarter and the pre-tax result was still negative, so the recovery is not yet reflected in pre-tax profitability.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q2
- As of: 2026-09-30
- Promoter holding: +57.48%
- FII holding: +7.71%
- DII holding: +18.86%
- Mutual fund holding: +16.93%
- Retail holding: +7.25%
- Promoter pledged: +0.00%

### Major reported shareholders

- BEHRYANDA LIMITED — +33.34% (Bodies Corporate)
- JUSMIRAL HOLDINGS LIMITED — +24.15% (Bodies Corporate)
- JASUB PROPERTY HOLDINGS LLP — +3.84%
- SBI MNC FUND — +3.73%
- ICICI PRUDENTIAL HEALTHCARE FUND — +3.68%
- DSP FLEXI CAP FUND — +2.90%
- JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED — +2.51%
- AMANSA HOLDINGS PRIVATE LIMITED — +2.18%
- HDFC TRUSTEE COMPANY LIMITED - HDFC TAX SAVERFUND — +2.16%
- SBI LIFE INSURANCE CO. LTD — +1.75%

## Official filings

- 2026-11-07 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_07112026105953_Cohance_conferencecallaudiolink7Nov26.pdf)
- 2026-11-07 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_07112026111339_Cohance_USFDA_disclosure_7Nov26.pdf)
- 2026-11-07 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_07112026135939_Cohance_Newspaperadvt_07112026.pdf)
- 2026-11-07 — Earnings Presentation: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_07112026164941_Cohance_Investor_Presentation_06112026.pdf)
- 2026-11-06 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_06112026082040_Cohance_PCB_order_disclosure_6Nov26.pdf)
- 2026-11-06 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_06112026131252_Cohance_SE_disclosure_ESOP_06112026.pdf)
- 2026-11-06 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_06112026174827_Cohance_Outcome_BM_06112026_uploading.pdf)
- 2026-11-06 — Press Release: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_06112026180529_Cohance_Pressrelease_06112026.pdf)
- 2026-11-06 — Earnings Presentation: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_06112026180222_Cohance_Investor_Presentation_06112026.pdf)
- 2026-11-06 — Financial Results Filing: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1755100_06112026073742_WEB.xml)
- 2026-11-06 — Financial Results Filing: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1755099_06112026073736_WEB.xml)
- 2026-11-06 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_17775_WebXMLFile_20261106_194254468.xml)
- 2026-11-03 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_03112026193202_Cohance_Q2_Concal_Invite_06112026_.pdf)
- 2026-10-27 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_27102026125928_Cohance_Q2_Concal_Invite_06112026_.pdf)
- 2026-10-26 — Board Meeting Notice: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_26102026181153_Cohance_BM_Intimation_06112026.pdf)
- 2026-10-26 — Board Meeting Notice: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_17775_WebXMLFile_20261026_181859117.xml)
- 2026-10-26 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_17775_WebXMLFile_20261026_181859117.xml)
- 2026-10-15 — Shareholding Disclosure: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1739335_15102026071315_WEB.xml)
- 2026-10-12 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_12102026194926_SE_disclosure_CG_Approval_Umang_Vohra.pdf)
- 2026-10-09 — Management Change: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_09102026201959_Cohance_Outcome_BM_09102026.pdf)
- 2026-10-09 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_17775_WebXMLFile_20261009_202739619.xml)
- 2026-10-09 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_09102026234023_Cohance_ESOP_Grant_09Oct2026.pdf)
- 2026-10-07 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_07102026183316_COHANCE_Certificate_Reg_74_5__30092026.pdf)
- 2026-09-28 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUVENPHARMROHIT_28092026142039_Closure_of_Trading_Window_28Sept26.pdf)
- 2026-09-28 — Generic Announcement: Cohance Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_17775_WebXMLFile_20260928_142318671.xml)

## News and market events

- 2026-11-06 — CNBC-TV18: **Cohance Lifesciences Q2 Results: Net profit plunges 80% on lower revenue, unfavourable product mix** — Cohance Lifesciences reported an 80% year-on-year plunge in Q2 FY27 net profit to ₹15.2 crore and a 14.2% revenue decline to ₹477 crore, driven by lower volumes and an unfavorable product mix that compressed gross margins. Despite the sharp drop in earnings before interest, tax, depreciation, and amortisation, the company anticipates a materially stronger second half of FY27 supported by small molecule deliveries, reload orders, and growth in its nucleic acid business. — [Source](https://www.cnbctv18.com/market/stocks/cohance-lifesciences-share-price-q2-results-net-profit-plunges-80-on-lower-revenue-unfavourable-product-mix-20029136.htm)
- 2026-11-06 — The Hindu: **Cohance Lifesciences manufacturing site in Telangana shut after worker dies in accident** — Cohance Lifesciences has shut its manufacturing site in Suryapet, Telangana, after the state pollution control board ordered closure following a fatal industrial accident that killed an employee. The company stated it is implementing corrective and preventive measures to address regulatory observations and expects to submit compliance documents promptly to resume operations. — [Source](https://www.thehindubusinessline.com/companies/cohance-lifesciences-manufacturing-site-in-telanganashut-after-worker-dies-in-accident/article71672770.ece)
- 2026-11-06 — MONEYCONTROL: **Cohance Lifesciences plant ordered shut in Telangana after employee dies in industrial accident** — The Telangana government has ordered the shutdown of a Cohance Lifesciences plant following an industrial accident that resulted in the death of an employee. This regulatory action targets the specific facility after the fatal incident occurred at the site. — [Source](https://www.moneycontrol.com/news/business/cohance-lifesciences-plant-ordered-shut-in-telangana-after-employee-dies-in-industrial-accident-14072157.html)
- 2026-11-06 — BUSINESSTODAY: **Cohance shares in focus as Telangana site closed after industrial accident** — Shares of Cohance Lifesciences are in focus after the Telangana Pollution Control Board ordered the closure of its Suryapet manufacturing site following an industrial accident that resulted in an employee's death. The company has initiated corrective measures and plans to submit representations to seek cancellation of the closure order, while analysts maintain a 12-month target price of Rs 472 for the stock. — [Source](https://www.businesstoday.in/markets/stocks/story/cohance-shares-in-focus-as-telangana-site-closed-after-industrial-accident-566084-2026-11-06)
- 2026-09-21 — CNBC-TV18: **FIIs turn net sellers, offload ₹576 crore on Monday; DIIs remain buyers** — Foreign institutional investors turned net sellers on Monday, offloading ₹576 crore after buying ₹600 crore on Friday. — [Source](https://www.cnbctv18.com/market/fiis-turn-net-sellers-offload-%25e2%2582%25b9576-crore-on-monday-diis-remain-buyers-19995099.htm)
- 2026-09-21 — CNBC-TV18: **Sensex jumps 564 points, Nifty ends above 23,400: 5 reasons behind today's market rally** — The Sensex rose 564 points to 74,859, while the Nifty Bank gained 112 points to 56,471. The Nifty Midcap index, however, fell 178 points to 62,013. — [Source](https://www.cnbctv18.com/market/sensex-jumps-564-points-nifty-ends-above-23400-5-reasons-behind-todays-market-rally-19994934.htm)
- 2026-09-21 — CNBC-TV18: **Cohance Lifesciences shares gain over 5% even as Andhra API unit gets five USFDA observations** — Cohance Life has not disclosed the nature of the five observations in its latest filing. The company though has launched its Corrective and Preventive Action Plan and will submit its response within the stipulated timeline. — [Source](https://www.cnbctv18.com/market/cohance-lifesciences-share-price-api-facility-andhra-pradesh-usfda-form-483-five-observations-impact-19994720.htm)
- 2026-09-08 — MONEYCONTROL: **Axis AMC PMS fund dumps DMart on q-comm squeeze, exits REC over state discom credit risks** — Axis AMC, PMS, Alternates, Axis brokerage. portfolio management — [Source](https://www.moneycontrol.com/news/business/markets/axis-amc-pms-fund-dumps-dmart-on-q-comm-squeeze-exits-rec-over-state-discom-credit-risks-14024970.html)
- 2026-09-07 — BUSINESSTODAY: **Top stocks in news: JSW Steel, TMCV, Mazagon, RVNL, Lupin, Molbio, Purple Style, HEG, Lemon Tree** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, JSW Steel, Tata Motors, TMCV, Mazagon Dock Engineering, RVNL, Rail Vikas Nigam, Lupin, Molbio Diagnostics, Purple Style Labs, HEG, Lemon Tree Hotels, Shiprocket, Behari Lal Engineering, Mazagon Dock Shipbuilders, Lemon Tree Hotels, Cohance Lifesciences, Urban Enviro Waste Management, Brigade Enterprises, Price Focus, Nava, Jayaswal Neco Industries — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-jsw-steel-tmcv-mazagon-rvnl-lupin-molbio-purple-style-heg-lemon-tree-blel-553519-2026-09-07)
- 2026-09-04 — The Hindu: **Cohance Lifesciences investing $18 million in NJ Bio, Aruka Bio to sharpen focus on ADC** — Cohance Lifesciences invests $18 million in NJ Bio and Aruka Bio to enhance its antibody-drug conjugate strategy and partnerships. — [Source](https://www.thehindu.com/business/industry/cohance-lifesciences-investing-18-million-in-nj-bio-aruka-bio-to-sharpen-focus-on-adc/article71427415.ece)
- 2026-09-04 — MONEYCONTROL: **Price Action: WeWork India rises 3% on solar plant approval; Shanthi Gears jumps 5% after CFO appointment** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/stocks/price-action-wework-india-rises-3-on-solar-plant-approval-shanthi-gears-jumps-5-after-cfo-appointment-14022429.html)
- 2026-09-04 — The Hindu: **Stocks in focus: IEX, PowerGrid, RVNL, APSEZ, Bharat Forge, HEG, brokerage stocks,Cipla among dozen stocks will be in focus** — IEX logs record August volumes; HEG renamed as scheme takes effect — [Source](https://www.thehindubusinessline.com/markets/stocks-in-focus-iex-powergrid-rvnl-apsez-bharat-forge-heg-brokerage-stockscipla-among-dozen-stocks-will-be-in-focus/article71426821.ece)
- 2026-08-24 — Economic Times: **Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?** — Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity. — [Source](https://economictimes.indiatimes.com/markets/ipos/fpos/can-symbiotec-pharmalab-ipo-deliver-long-term-growth-for-high-risk-investors/articleshow/133448856.cms)
- 2026-08-18 — MONEYCONTROL: **Cohance's Umang Vohra says the worst is over; market looks for signs of recovery** — Umang Vohra, Cohance Lifesciences, Advent International, Advent, Suven Pharma, CDMO, API, Vivek Sharma, NJ Bio, ADCs — [Source](https://www.moneycontrol.com/news/business/cohance-s-umang-vohra-says-the-worst-is-over-market-looks-for-signs-of-recovery-14009140.html)
- 2026-08-06 — MONEYCONTROL: **Reduce Cohance Lifesciences; target of Rs 365: ICICI Securities** — ICICI Securities, reduce, Cohance Lifesciences, Recommendation — [Source](https://www.moneycontrol.com/news/business/stocks/reduce-cohance-lifesciences-target-of-rs-365-icici-securities-13996415.html)
- 2026-08-06 — The Hindu: **Sensex today | Stock Market Live: Sensex up 200 pts, Nifty holds 24,600 in choppy trade; Reliance, BEL lead gainers; TTK Healthcare shares jump 15% on strong Q1** — Sensex, Nifty, Share Prices LIVE: Benchmark indices edged higher at the open ‌on Thursday, supported by hopes of a diplomatic breakthrough ⁠in the Middle East and a better-than-expected June-quarter earnings season. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-6-august-2026/article71309748.ece)
- 2026-08-06 — MONEYCONTROL: **Buzzing Stocks: Kolte-Patil Developers jumps 5% on project wins; Godrej Agrovet slips after weak Q1 earnings** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/buzzing-stocks-kolte-patil-developers-jumps-5-on-project-wins-godrej-agrovet-slips-after-weak-q1-earnings-13995977.html)
- 2026-08-06 — MONEYCONTROL: **Cohance Life shares in focus after USFDA flags five observations; Q1 loss widens** — Cohance Lifesciences,Cohance Lifesciences share price live today — [Source](https://www.moneycontrol.com/news/business/markets/cohance-life-shares-in-focus-after-usfda-flags-five-observations-q1-loss-widens-13995635.html)
- 2026-08-05 — The Hindu: **Cohance Lifesciences reports ₹45.19 crore loss in Q1 on lower revenue** — Cohance Lifesciences reports ₹45.19 crore Q1 loss due to lower revenue, despite growth in subsidiaries and API performance. — [Source](https://www.thehindu.com/business/industry/cohance-lifesciences-reports-4519-crore-loss-in-q1-on-lower-revenue/article71310648.ece)
- 2026-08-05 — CNBC-TV18: **Stocks to Watch for August 6: Cummins India, Biocon, PB Fintech and more** — Stocks such as Navin Fluorine International, Cummins India, PB Fintech, JK Lakshmi Cement, Neuland Laboratories and Aster DM Quality Care will be in focus on Thursday after reporting their June-quarter earnings post market hours on Wednesday. Investors will also track companies scheduled to announce their June-quarter results during the day for stock-specific cues. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-6-cummins-india-biocon-pb-fintech-and-more-19962532.htm)
- 2026-08-05 — CNBC-TV18: **Stocks to Watch for August 6: Cummins India, Biocon, PB Fintech and more** — Stocks such as Navin Fluorine International, Cummins India, PB Fintech, JK Lakshmi Cement, Neuland Laboratories and Aster DM Quality Care will be in focus on Thursday after reporting their June-quarter earnings post market hours on Wednesday. Investors will also track companies scheduled to announce their June-quarter results during the day for stock-specific cues. — [Source](https://www.cnbctv18.com/market/stocks-to-watch-for-august-6-cummins-india-biocon-pb-fintech-and-more-19962532.htm)
- 2026-08-05 — CNBC-TV18: **Cohance Lifesciences’ Hyderabad plant gets USFDA observations: What it means for the pharma maker** — Cohance Lifesciences received five observations from the USFDA after an inspection of its Hyderabad manufacturing facility. The company said the findings do not involve data integrity issues and it is working on corrective measures to address the regulator’s concerns. — [Source](https://www.cnbctv18.com/business/companies/cohances-hyderabad-facility-gets-five-usfda-observations-after-inspection-19962649.htm)
- 2026-07-22 — News18: **Lupin, Aurobindo, Cipla Fall Up To 2.9%: Pharma Stocks Under Pressure As Trump's Tariff Roadmap Rattles Sentiment** — Lupin falls 2.88%, Aurobindo Pharma declines 2.73%, Alkem Laboratories slips 2.44%, Zydus Lifesciences drops 2.20%, while Cipla slips 2.09%. — [Source](https://www.news18.com/business/markets/lupin-aurobindo-cipla-fall-up-to-2-9-pharma-stocks-under-pressure-as-trumps-tariff-roadmap-rattles-sentiment-ws-l-10226502.html)

## Business profile

**Strategic vision:** Global CDMO for pharmaceutical and chemical product lifecycles.

### Business segments
- **Small Molecule API:** Offers end-to-end solutions for Small Molecule API development and manufacturing, from early-phase process design to commercial supply, handling complex and high-potency APIs.
- **Nucleic Acid Chemistry:** Provides custom nucleic acid synthesis, process development, scale-up, and GMP manufacturing for therapeutic companies developing drugs based on oligonucleotides and other emerging modalities.
- **Generic APIs:** Operates an integrated Generic API platform serving a global customer base with over 50 molecules across various therapeutic areas, supported by 8 cGMP facilities.
- **Specialty Chemicals:** Delivers advanced solutions in Agrochemicals and Performance Chemicals, integrating scientific expertise, scalable manufacturing, and regulatory excellence for various industries.

### Competitive strengths
- Expertise in handling complex, sensitive, and high-potency APIs.
- Robust safety assessments and regulatory compliance.
- Extensive experience in nucleic acid chemistry and custom synthesis.
- Global regulatory expertise and a reliable supply network for generic APIs.
- Integration of scientific expertise, scalable manufacturing, and regulatory excellence in specialty chemicals.

## Related stocks

- [Acutaas Chemicals Limited (Healthcare)](https://faxioms.com/stocks/acutaas) — +0.30%
- [Blue Jet Healthcare Limited (Healthcare)](https://faxioms.com/stocks/bluejet) — -3.23%
- [Caplin Point Laboratories Limited (Healthcare)](https://faxioms.com/stocks/caplipoint) — -1.64%
- [Concord Biotech Limited (Healthcare)](https://faxioms.com/stocks/concordbio) — -6.64%
- [Eris Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/eris) — +0.58%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/cohance
Markdown representation: https://faxioms.com/stocks/cohance?render=md